Characterization of the mutational profile of 11 diffuse large B-cell lymphoma cell lines

References

• Weinstein JN, Pommier Y. Transcriptomic analysis of the NCI-60 cancer cell lines. C R Biol. 2003;326:909–920.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Dalla-Favera R. The genetic landscape of diffuse large B-cell lymphoma. Semin Hematol. 2015;52:67–76.
   PubMed Web of Science ®Google Scholar
• Young RM, Shaffer AL 3rd, Phelan JD, et al. B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol. 2015;52:77–85.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
   PubMed Web of Science ®Google Scholar
• Dai H, Ehrentraut S, Nagel S, et al. Genomic landscape of primary mediastinal B-cell lymphoma cell lines. PLoS One. 2015;10:e0139663.
   PubMed Web of Science ®Google Scholar
• Drexler HG, Ehrentraut S, Nagel S, et al. Malignant hematopoietic cell lines: in vitro models for the study of primary mediastinal B-cell lymphomas. Leuk Res. 2015;39:18–29.
   PubMed Web of Science ®Google Scholar
• iclac.org [Internet]. Guide to human cell line authentication; [cited 2017 Aug 10]. Available from: http://iclac.org/wp-content/uploads/Authentication-SOP_09-Jan-Q1 2014.pdf
   Google Scholar
• Juskevicius D, Lorber T, Gsponer J, et al. Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis. Leukemia. 2016;30(12):2385–2395.
   PubMed Web of Science ®Google Scholar
• Forbes SA, Beare D, Gunasekaran P, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43:D805–D811.
   PubMed Web of Science ®Google Scholar
• Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–607.
   PubMed Web of Science ®Google Scholar
• Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2013;110:1398–1403.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43:830–837.
   PubMed Web of Science ®Google Scholar
• Quentmeier H, Amini RM, Berglund M, et al. U-2932: two clones in one cell line, a tool for the study of clonal evolution. Leukemia. 2013;27:1155–1164.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mungall K, Pleasance E, et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood. 2013;122:1256–1265.
   PubMed Web of Science ®Google Scholar
• Drexler HG, Eberth S, Nagel S, et al. Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas. Leuk Lymphoma. 2016;57:1015–1020.
   PubMed Web of Science ®Google Scholar
• Cao S, Strong MJ, Wang X, et al. High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project. J Virol. 2015;89:713–729.
   PubMed Web of Science ®Google Scholar
• Drexler HG, MacLeod RA. Malignant hematopoietic cell lines: in vitro models for the study of Waldenström's macroglobulinemia. Leuk Res. 2008;32:1669–1673.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476:298–303.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Wu L, Visco C, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012;120:3986–3996.
   PubMed Web of Science ®Google Scholar
• Leroy B, Girard L, Hollestelle A, et al. Analysis of TP53 mutation status in human cancer cell lines: a reassessment. Hum Mutat. 2014;35:756–765.
   PubMed Web of Science ®Google Scholar
• Sen S, Zhou H, Andersson BS, et al. p53 gene mutations with chromosome 17 abnormalities in chronic myelogenous leukemia blast crisis patients persist in long-term cell lines but may be acquired in acute myeloid leukemia cells in vitro. Cancer Genet Cytogenet. 1995;82:35–40.
   PubMedGoogle Scholar
• Ollikainen H, Syrjanen S, Koskela K, et al. p53 gene mutations are rare in patients but common in patient-originating cell lines in multiple myeloma. Scand J Clin Lab Invest. 1997;57:281–289.
   PubMed Web of Science ®Google Scholar
• Drexler HG, Fombonne S, Matsuo Y, et al. p53 alterations in human leukemia-lymphoma cell lines: in vitroartifact or prerequisite for cell immortalization? Leukemia. 2000;14:198–206.
   PubMed Web of Science ®Google Scholar
• Laursen MB, Falgreen S, Bodker JS, et al. Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma. Exp Hematol. 2014;42:927–938.
   PubMed Web of Science ®Google Scholar
• DSMZ: Catalogue Human and Animal Cell Lines. Braunschweig, Germany: Leibniz-Institute DSMZ; 2017. Available from: http://www.dsmz.de/catalogues/catalogue-human-and-animal-cell-lines.html
   Google Scholar
• Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115–119.
   PubMed Web of Science ®Google Scholar
• Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 2010;10:241–253.
   PubMed Web of Science ®Google Scholar
• Khodabakhshi AH, Morin RD, Fejes AP, et al. Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget. 2012;3:1308–1319.
   PubMed Web of Science ®Google Scholar
• Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88–92.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Kanegai CM, Doerr JR, et al. Somatic hypermutation of the B cell receptor genes B29 (Igbeta,CD79b) and mb1 (Igalpha,CD79a). Proc Natl Acad Sci USA. 2003;100:4126–4131.
   PubMed Web of Science ®Google Scholar